<DOC>
	<DOCNO>NCT02175173</DOCNO>
	<brief_summary>This surveillance 's objective 1 . Unknown adverse reaction 2 . Incidences adverse drug reaction 3 . Efficacy long-term administration 4 . Factors consider effect safety effectiveness 5 . Incidences status epileptic , skin disorder hyper sensitivity reaction , central nervous system-related adverse event ( ataxia , somnolence and/or dizzy , etc . )</brief_summary>
	<brief_title>Post-marketing Surveillance Long-term Administration Inovelon Tablets Patients With Lennox-Gastaut Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lennox Gastaut Syndrome</mesh_term>
	<criteria>All patient LennoxGastaut syndrome administrate Inovelon</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Epileptic encephalopathy , Lennox-Gastaut type</keyword>
</DOC>